Long-term protective effects of zoledronic acid on cancellous and cortical bone in the ovariectomized rat

Journal of Bone and Mineral Research

Volumn 23, Issue 4, 2008, Pages 544-551

  Gasser, Jürg A ^a   Ingold, Peter ^a   Venturiere, Andrea ^a   Shen, Victor ^b   Green, Jonathan R ^a  

^a NOVARTIS PHARMA AG   (Switzerland)

^b Skele Tech Inc   (United States)

Author keywords

Bisphosphonate; Bone loss; Osteoporosis; Single dose; Zoledronic acid

Indexed keywords

ALENDRONIC ACID; FLUOROCHROME; MARKER; PROTEIN DERIVATIVE; SODIUM CHLORIDE; TRACP5B PROTEIN; UNCLASSIFIED DRUG; ZOLEDRONIC ACID;

ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ARCHITECTURE; ARTICLE; ATTENUATION; BIOMECHANICS; BONE DENSITY; BONE MASS; BONE STRENGTH; BONE TURNOVER; CANCELLOUS BONE; COMPARATIVE STUDY; COMPRESSION; CONTROLLED STUDY; CORTICAL BONE; DOSE RESPONSE; DRUG EFFECT; DRUG POTENCY; DYNAMICS; FEMALE; MORPHOMETRICS; NONHUMAN; OSSIFICATION; OSTEOCLAST; OSTEOLYSIS; OSTEOPENIA; OSTEOPOROSIS; OVARIECTOMY; POSTMENOPAUSE; PROTECTION; RAT; SHAM PROCEDURE; STATISTICAL SIGNIFICANCE; TRABECULAR BONE; WISTAR RAT;

ANIMALS; BONE AND BONES; BONE DENSITY; DIPHOSPHONATES; FEMALE; IMIDAZOLES; OSTEOCALCIN; OVARIECTOMY; RATS; RATS, WISTAR;

EID: 41849119494     PISSN: 08840431     EISSN: None     Source Type: Journal    
DOI: 10.1359/jbmr.071207     Document Type: Article

References (31)

1. Green JR, Muller K, Jaeggi KA 1994 Preclinical pharmacology of CGP 42'446, a new, potent, heterocyclic bisphosphonate compound. J Bone Miner Res 9:745-751.
2. Glatt M, Pataki A, Evans GP, Hornby SB, Green JR 2004 Loss of vertebral bone and mechanical strength in estrogen-deficient rats is prevented by long-term administration of zoledronic acid. Osteoporos Int 15:707-715.
3. Hornby SB, Evans GP, Hornby SL, Pataki A, Glatt M, Green JR 2003 Long-term zoledronic acid treatment increases bone structure and mechanical strength of long bones of ovariectomized adult rats. Calcif Tissue Int 72:519-527.
4. Binkley N, Kimmel D, Bruner J, Haffa A, Davidowitz B, Meng C, Schaffer V, Green J 1998 Zoledronate prevents the development of absolute osteopenia following ovariectomy in adult rhesus monkeys. J Bone Miner Res 13:1775-1782.
5. Hosking D, Lyles K, Brown JP, Fraser WD, Miller P, Diaz Curiel M, Devogelaer JP, Hooper M, Su G, Zelenakas K, Pak J, Fashola T, Saidi Y, Fink Eriksen E, Reid IR 2007 Long term control of bone turnover in Paget's disease with zoledronic acid and risedronate. J Bone Miner Res 22:142-148.
6. Black DM, Delmas P, Eastell R, Reid I, Boonen S, Cauley J, Cosman F, Lakatos P, Leung PC, Man Z, Mautalen C, Mesenbrink P, Hu H, Caminis J, Tong K, Rosario-Jansen T, Krasnow J, Hue TF, Sellmeyer D, Eriksen EF, Cummings SR for the HORIZON Pivotal Fracture Trial 2007 Once-yearly zoledronic acid for treatment of postmenopausal osteoporosis. N Engl J Med 356:1809-1822.
7. Rogers M 2004 From molds and macrophages to mevalonate: A decade of progress in understanding the molecular mode of action of bisphosphonates. Calcif Tissue Int 75:451-461.
8. Hughes DE, MacDonald BR, Russell RGG, Gowen M 1989 Inhibition of osteoclast-like cell formation by bisphosphonates in long-term cultures of human bone marrow. J Clin Invest 83:1930-1935.
9. Löwik CWGM, van der Pluijm G, van der Wee-Pals LJA, van Treslong-De Groot HB, Bijvoet OL 1988 Migration and phenotypic transformation of osteoclast precursors into mature osteoclasts: The effect of a bisphosphonate. J Bone Miner Res 3:185-192.
10. Sato M, Grasser W, Endo N, Akins R, Simmons H, Thompson DD, Golub E, Rodan GA 1991 Bisphosphonate action. Alendronate localization in rat bone and effects on osteoclast ultrastructure. J Clin Invest 88:2095-2105.
11. Zimolo Z, Wesolowski G, Rodan GA 1995 Acid extrusion is induced by osteoclast attachment to bone. Inhibition by alendronate and calcitonin. J Clin Invest 96:2277-2283.
12. Selander KS, Monkkonen J, Karhukorpi EK, Harkonen P, Hannuniemi R, Vaananen HK 1996 Characteristics of clodronate-induced apoptosis in osteoclasts and macrophages. Mol Pharmacol 50:1127-1138.
13. Hughes DE, Wright KR, Uy HL, Sasaki A, Yoneda T, Roodman GD, Mundy GR, Boyce BF 1995 Bisphosphonates promote apoptosis in murine osteoclasts in vitro and in vivo. J Bone Miner Res 10:1478-1487.
14. Amin D, Cornell SA, Gustafson SK, Needle SJ, Ullrich JW, Bilder GE, Perrone MH 1992 Bisphosphonates used for the treatment of bone disorders inhibit squalene synthase and cholesterol biosynthesis. J Lipid Res 33:1657-1663.
15. Luckman SP, Hughes DE, Coxon FP, Graham R, Russell G, Rogers MJ 1998 Nitrogen-containing bisphosphonates inhibit the mevalonate pathway and prevent post-translational prenylation of GTP-binding proteins, including Ras. J Bone Miner Res 13:581-589.
16. Luckman SP, Coxon FP, Ebetino FH, Russell RG, Rogers MJ 1998 Heterocycle-containing bisphosphonates cause apoptosis and inhibit bone resorption by preventing protein prenylation: Evidence from structure-activity relationships in J774 macrophages. J Bone Miner Res 13:1668-1678.
17. Fisher JE, Rogers MJ, Halasy JM, Luckman SP, Hughes DE, Masarachia PJ, Wesolowski G, Russell RG, Rodan GA, Reszka AA 1999 Alendronate mechanism of action: Geranylgeraniol, an intermediate in the mevalonate pathway, prevents inhibition of osteoclast formation, bone resorption, and kinase activation in vitro. Proc Natl Acad Sci USA 96:133-138.
18. Casey PJ 1995 Protein lipidation in cell signaling. Science 268:221-225.
19. Gasser JA 1995 Quantitative assessment of bone by pQCT. Bone 17:145-154.
20. Gasser JA, Ingold P, Grosios K, Laib A, Hämmerle S, Koller B 2005 Non-invasive monitoring of changes in structural cancellous bone parameters with a novel prototype microCT. J Bone Miner Metab 23(Suppl):90-96.
21. Parfitt AM, Drezner MK, Glorieux FH, Kanis JA, Malluche H, Meunier PJ, Ott SM, Recker RR 1987 Bone histomorphometry: Standardization of nomenclature, symbols, and units. Report of the ASBMR Histomorphometry Nomenclature Committee. J Bone Miner Res 2:595-610.
22. Thomsen JS, Mosekilde L, Gasser JA 1999 Long-term therapy of ovariectomy-induced osteopenia with parathyroid hormone analog SDZ PTS 893 and bone maintenance in retired breeder rats. Bone 25:561-569.
23. Turner CH, Burr DB 1993 Basic biomechanical measurements of bone: A tutorial. Bone 14:595-608.
24. O'Doherty DP, McCloskey EV, Vasikaran S, Khan S, Kanis JA 1995 The effects of intravenous alendronate in Paget's disease of bone. J Bone Miner Res 10:1094-1100.
25. Vasikaran SD, Khan S, McCloskey EV, Kanis JA 1995 Sustained response to intravenous alendronate in postmenopausal osteoporosis. Bone 17:517-520.
26. Adami S, Bevilacqua M, Broggini M, Filipponi P, Ortolani S, Palummeri E, Ulivieri F, Nannipieri F, Braga V 2002 Short-term intravenous therapy with neridronate in Paget's disease. Clin Exp Rheumatol 20:55-58.
27. Boivin GY, Chavassieux PM, Santora AC, Yates J, Meunier PJ 2000 Alendronate increases bone strength by increasing the mean degree of mineralization of bone tissue in osteoporotic women. Bone 27:687-694.
28. Roschger P, Rinnerthaler S, Yates J, Rodan GA, Fratzl P, Klaushofer K 2001 Alendronate increases degree and uniformity of mineralization in cancellous bone and decreases the porosity in cortical bone of osteoporotic women. Bone 29:185-191.
29. Burr DB, Miller L, Grynpas M, Li J, Boyde A, Mashiba T, Hirano T, Johnston CC 2003 Tissue mineralization is increased following 1-year treatment with high doses of bisphosphonates in dogs. Bone 33:960-969.
30. Zoehrer R, Roschger P, Paschalis EP, Hofstaetter JG, Durchschlag E, Fratzl P, Phipps R, Klaushofer K 2006 Effects of 3-and 5-year treatment with risedronate on bone mineralization density distribution in triple biopsies of the iliac crest in postmenopausal women. J Bone Miner Res 21:1106-1112.
31. Durchschlag E, Paschalis EP, Zoehrer R, Roschger P, Fratzl P, Recker R, Phipps R, Klaushofer K 2006 Bone material properties in trabecular bone from human iliac crest biopsies after 3- and 5-year treatment with risedronate. J Bone Miner Res 21:1581-1590.